Advertisement

Search Results

Advertisement



Your search for ,USE matches 11265 pages

Showing 11251 - 11265


Study Shows New Approach Connecting Smokers to Quit Lines Increases Smoking Cessation Treatment Enrollment

Self-identified smokers directly connected to a tobacco cessation quit line are 13 times more likely to enroll in a treatment program as compared to smokers who are handed a quit line referral card and encouraged to call on their own, according to a new study published online in JAMA Internal...

breast cancer

Breast Cancer Patients’ Fear of Developing Lymphedema Far Exceeds Risk

Women who have had the lymph nodes under their arm surgically removed during breast cancer treatment are warned to avoid certain practices that can cause lymphedema. Now, a new study published in the March issue of the Journal of the American College of Surgeons suggests that the vast majority of...

solid tumors

FDA Approves Regorafenib for Advanced Gastrointestinal Stromal Tumors

The FDA has expanded the approved use of regorafenib (Stivarga) to treat patients with metastatic or unresectable gastrointestinal stromal tumors (GIST) that no longer respond to treatment with imatinib (Gleevec) or sunitinib (Sutent). Regorafenib, a multikinase inhibitor, blocks several enzymes...

hematologic malignancies
leukemia
survivorship

Risk of Leukemia After Cancer Chemotherapy Persists

While advancements in cancer treatment over the last several decades have improved patient survival rates for certain cancers, some patients remain at risk of developing treatment-related leukemia, according to results of a study published online in Blood, the Journal of the American Society of...

multiple myeloma

FDA Approves Pomalidomide for Advanced Multiple Myeloma

The FDA approved pomalidomide (Pomalyst) to treat patients with multiple myeloma whose disease progressed after being treated with other cancer drugs. Pomalidomide, an oral immunomodulatory agent, is intended for patients who have received at least two prior therapies, including lenalidomide...

lymphoma

Experimental Drug Combination Selectively Destroys Lymphoma Cells

Laboratory experiments conducted by researchers at Virginia Commonwealth University Massey Cancer Center suggest that a novel combination of the investigational agent ibrutinib and bortezomib (Velcade) could potentially be an effective new therapy for several forms of blood cancer, including...

lymphoma

High-dose Vorinostat Effective at Treating Relapsed Lymphomas, Study Finds

Reporting the results of a phase I clinical trial to test the effectiveness of a new class of drugs to augment standard chemotherapy, a team led by Fred Hutchinson Cancer Research Center scientists found that giving patients high doses of vorinostat (Zolinza) in combination with another round...

breast cancer
integrative oncology

MD Anderson Study Finds Qigong Improves Quality of Life for Breast Cancer Patients Undergoing Radiation Therapy

Researchers from The University of Texas MD Anderson Cancer Center have found qigong, an ancient mind-body practice, reduces depressive symptoms, and improves quality of life in women undergoing radiotherapy for breast cancer. The study, published in the journal Cancer, is the first to examine...

leukemia

Imatinib Receives New Indication for Children with Acute Lymphoblastic Leukemia

The FDA approved a new use of imatinib (Gleevec) to treat children newly diagnosed with Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL). ALL is the most common type of pediatric cancer, affecting approximately 2,900 children annually, and progresses quickly if untreated....

colorectal cancer

Bevacizumab Approved as Combination Therapy for Metastatic Colorectal Cancer after Progression on First-line Bevacizumab Therapy

On January 23, 2013, the FDA approved bevacizumab (Avastin) for use in combination with fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin based chemotherapy for the treatment of patients with metastatic colorectal cancer whose disease has progressed on a first-line bevacizumab-containing...

leukemia

Genetic Basis of High-risk Childhood Cancer Points to Possible New Drug Treatment Strategy

Research led by St. Jude Children’s Research Hospital scientists has identified a possible lead in treatment of two childhood leukemia subtypes known for their dramatic loss of chromosomes and poor treatment outcomes. The findings also provide the first evidence of the genetic basis for ...

colorectal cancer

New Model May Help Predict Response to Chemotherapy for Colorectal Cancer

Scientists may be able to better predict which patients with colorectal cancer will respond to chemotherapy using a new mathematical model that measures the amount of stress required for a cancer cell to die without harming healthy tissue. The results of this study are published in Cancer Research, ...

lung cancer

Patients with NSCLC Have Improved Survival If They Use Beta-blockers While Receiving Radiotherapy

Patients with non–small cell lung cancer (NSCLC) have improved survival outcomes if they are taking beta-blockers while receiving radiotherapy, according to a study of 722 patients recently published in Annals of Oncology. Researchers at the University of Texas MD Anderson Cancer Center in...

Report to the Nation Shows U.S. Cancer Death Rates Continue to Drop

The Annual Report to the Nation on the Status of Cancer, 1975–2009, shows that overall cancer death rates continued to decline in the United States among both men and women, among all major racial and ethnic groups, and for all of the most common cancer sites, including lung, colon and...

Improving Outcomes for Patients With Non–Small Cell Lung Cancer

For over a decade, the treatment landscape of non–small cell lung cancer (NSCLC) has been rapidly evolving. It now includes testing for genetic alterations and the use of targeted therapies and immunotherapies, with new targets and treatments still being discovered and approved. In this six-part...

Advertisement

Advertisement




Advertisement